Loading company
$76.990.0%Aug 26 close
Figures through June 30, 2026, from the 10-Q filed August 12, 2026
Past performance
- 3M
- +0.2%
- 6M
- +233%
- 1Y
- +447%
- 5Y
- -6.1%
$76.990.0%Aug 26 close
Figures through June 30, 2026, from the 10-Q filed August 12, 2026
The quarter ending December 31, 2019, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2019 | 3 months toDec 31, 2018 | Change |
|---|---|---|---|
| Total Revenue | $9K | $9K | 0.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Forte Biosciences, Inc. has no earnings call transcript available.
“FB102 received Fast Track Designation from the FDA in celiac disease, highlighting the unmet need and reinforcing FB102’s potential to address the high unmet need in celiac disease. The clinical development for FB102 continues to progress well with important readouts coming shortly,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Forte Biosciences, Inc.’s Item 2.02 8-K filed May 14, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.